Sector portfolio · Private equity · Netherlands

Forbion Capital Partners' Biotech portfolio

Forbion Capital Partners has backed 54 Biotech startups in rounds we track, $7.0B between them, shown by the stage each has reached. The best-funded is Dyne Therapeutics.

54startups backed
5stages
$7.0Braised between them
Series Bbiggest stage

Forbion Capital Partners's whole portfolioForbion Capital Partners's profile

Series B

23

Series A

16

Series C and later

7

Stage not reported

6

Pre-seed and seed

2

Segment by segment

Series B

23 startups · $2.5B raised

  1. Expedition TherapeuticsExpedition Therapeutics is a biotechnology company based in San Francisco, founded in 2024.United States$280M
  2. Marea TherapeuticsMarea is a biotechnology firm that uses the advancements in human genetics next-generation medications for cardiometabolic illnesses.United States$190M
  3. CTCapstan TherapeuticsCapstan Therapeutics is advancing cell engineering to develop therapeutics for a broad range of diseases.United States$175M
  4. Mariana OncologyMariana Oncology is a biotechnology research industry.United States$175M
  5. AIRNAAIRNA is a biotechnology company founded in 2021, focused on discovering and developing RNA editing therapeutics.United States$155M
  6. Noema PharmaNoema Pharma is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 by George Garibaldi and Luigi Costa.Switzerland$147M
  7. Achilles TherapeuticsAchilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.United Kingdom$143M
  8. AAVantgarde BioAAVantgarde Bio is developing gene therapies for inherited retinal disorders.Italy$141M

Series A

16 startups · $2.4B raised

  1. Dyne TherapeuticsDyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.United States$828M
  2. Verdiva BioVerdiva Bio is a clinical-stage biopharmaceutical company based in Guildford, United Kingdom, founded in 2024.United Kingdom$601M
  3. Braveheart BioBraveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.United States$185M
  4. Slate MedicinesSlate Medicines develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention.United States$130M
  5. MMMemento MedicinesMemento Medicines is a biotech developing bispecific antibody therapies for eye diseases.United Kingdom$93M
  6. Calluna PharmaCalluna Pharma is a clinical-stage biotechnology company based in Oslo, Norway.Norway$81M
  7. Corsera HealthCorsera Health is a biotechnology company based in Boston, founded in 2025 by John Maraganore, Ph.D., and Clive Meanwell, M.D.United States$80M
  8. MTMosanna TherapeuticsSwitzerland$80M

Series C and later

7 startups · $930M raised

  1. Beacon TherapeuticsBeacon Therapeutics is a clinical-stage ophthalmic gene therapy company founded in 2023, dedicated to saving and restoring vision United States$247M
  2. AM PharmaAM-Pharma is a Dutch clinical-stage biopharmaceutical company founded in 2001 and based in Utrecht, Netherlands.Netherlands$189M
  3. BBioVexTHOUSAND OAKS, Calif., March 4, 2011 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN), today announced the completion of the acquisUnited Kingdom$133M
  4. SANIFITSANIFIT is a biotechnology company that develops treatments for patients with calcification disorders.Spain$122M
  5. NorthSea TherapeuticsNorthSea Therapeutics B.V.Netherlands$109M
  6. HookipaHookipa GmbH – Private Equity, Finanzierungen, Start-Up Coaching und Vermittlung von Kontakten & Personal.Austria$97M
  7. KKaNDYUnited Kingdom$33M

Stage not reported

6 startups · $1.1B raised

  1. New Amsterdam PharmaNew Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.Netherlands$453M
  2. Crescent BiopharmaCrescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.United States$185M
  3. bluebird biobluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.United States$151M
  4. VectivBioVectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.Switzerland$125M
  5. GTGyroscope TherapeuticsGyroscope Therapeutics is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.United Kingdom$118M
  6. Mestag TherapeuticsMestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology.United Kingdom$42M

Pre-seed and seed

2 startups · $11M raised

  1. Tessellate BIOTessellate Bio is a preclinical-stage biotechnology company focused on developing innovative precision oncology medicines.Netherlands$8.5M
  2. CTCoviCept TherapeuticsCoviCept Therapeutics is focused on the development of a small molecule that inhibits the replication and spread of RNA viruses.-$2.3M

How this map is made. Every startup here works in Biotech and has raised money in a round we track that names Forbion Capital Partners as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.

More portfolio maps

All portfolios
Portfolio mapForbion Capital Partners portfolio map74 startups · $10BCo-investorsWho invests with Forbion Capital Partners55 co-investorsInvestments abroadForbion Capital Partners' investments in the United States25 startups · $4.6BInvestments abroadForbion Capital Partners' investments in the United Kingdom20 startups · $3.0BSector portfolioGilde Healthcare's Biotech portfolio11 startups · $1.3BSector portfolioY Combinator's AI portfolio1,143 startups · $44B

Raising from investors like Forbion Capital Partners?

Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.

Find investorsMarket maps